{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:41:44Z","timestamp":1790858504512,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.clinthera.2008.01.003","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T15:11:31Z","timestamp":1208445091000},"page":"195-205","source":"Crossref","is-referenced-by-count":33,"title":["Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States"],"prefix":"10.1016","volume":"30","author":[{"given":"JoAnne M.","family":"Foody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie T.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry Z.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.01.003_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2008.01.003_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre ran-domised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.01.003_bib6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.01.003_bib7","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.01.003_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of ator-vastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2008.01.003_bib10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.01.003_bib11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.amjcard.2006.04.033","article-title":"Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population","volume":"98","author":"Mehta","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1524-4733.2006.00163.x","article-title":"Reduced mortality rates after intensive statin therapy in managed-care patients","volume":"10","author":"Fintel","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2008.01.003_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/bmj.38398.408032.8F","article-title":"Statin use in the secondary prevention of coronary heart disease in primary care: Cohort study and comparison of inclusion and outcome with patients in randomised trials","volume":"330","author":"Wei","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2008.01.003_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82:128]","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1592\/phco.26.4.469","article-title":"Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting","volume":"26","author":"Bullano","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2008.01.003_bib19","doi-asserted-by":"crossref","first-page":"11F","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences of 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors con-tribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ahj.2005.04.003","article-title":"Are statins created equal? Evidence from randomized trials of pravastat-in, simvastatin, and atorvastatin for cardiovascular disease prevention","volume":"151","author":"Zhou","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2008.01.003_bib21","first-page":"1","article-title":"Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies","volume":"9","author":"Gresser","year":"2004","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.clinthera.2008.01.003_bib22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1185\/030079905X61866","article-title":"Differences between statins on clinical endpoints: A population-based cohort study","volume":"21","author":"Dieleman","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2008.01.003_bib23","first-page":"280","article-title":"Switching statins: The impact on patient outcomes","volume":"14","author":"Phillips","year":"2007","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02849887","article-title":"Medication adherence trends with statins","volume":"22","author":"Huser","year":"2005","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2008.01.003_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/hrt.2003.026187","article-title":"Long term persistence with statin treatment in daily medical practice","volume":"90","author":"Mantel-Teeuwisse","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2008.01.003_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/oxfordjournals.aje.a010011","article-title":"Invited commentary: Propensity scores","volume":"150","author":"Joffe","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2008.01.003_bib27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.01.003_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.01.003_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200767001-00007","article-title":"Atorvastatin: A safety and tolerability profile","volume":"67","author":"Arca","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2008.01.003_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ahj.2005.09.010","article-title":"Persistence and adher-ence to cholesterol lowering agents: Evidence from R\u00e9gie de l'Assurance Maladie du Qu\u00e9bec data","volume":"152","author":"Lachaine","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2008.01.003_bib31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ahj.2007.02.029","article-title":"Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration","volume":"153","author":"Blanco-Colio","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2008.01.003_bib32","first-page":"335","article-title":"Confounding by indication","volume":"7","author":"Walker","year":"1996","journal-title":"Epidemiology"},{"key":"10.1016\/j.clinthera.2008.01.003_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jama.286.10.1228","article-title":"How do ob-servational studies expand the evi-dence base for therapy?","volume":"286","author":"Radford","year":"2001","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T01:50:14Z","timestamp":1546134614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0149291808000519"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.01.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}